In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer and BioNTech said Friday that their combined mRNA vaccine candidate against influenza and Covid-19 showed a lower ...

BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line." The analyst in question also hiked its price target to ...

The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American ...

FRANKFURT, May 5 (Reuters) - BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 ...

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Germany s BioNTech said Tuesday it will halt operations at several sites, in a move affecting up to 1,860 jobs, as sales of ...

BioNTech is planning site closures affecting up to 1,860 jobs and will buy back $1 billion in shares after announcing the ...

The drug candidate, Trastuzumab Pamirtecan, also holds both FDA Fast Track and Breakthrough Therapy designations. Phase 3 trials are underway, and a Biologics License Application is planned for 2026.

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...

The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...